vs
Side-by-side financial comparison of Prelude Therapeutics Inc (PRLD) and SAGTEC GLOBAL Ltd (SAGT). Click either name above to swap in a different company.
Prelude Therapeutics Inc is the larger business by last-quarter revenue ($6.5M vs $3.8M, roughly 1.7× SAGTEC GLOBAL Ltd). SAGTEC GLOBAL Ltd runs the higher net margin — 19.7% vs -303.5%, a 323.1% gap on every dollar of revenue.
PRLD vs SAGT — Head-to-Head
Income Statement — Q3 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $6.5M | $3.8M |
| Net Profit | $-19.7M | $744.4K |
| Gross Margin | — | 36.4% |
| Operating Margin | -314.1% | — |
| Net Margin | -303.5% | 19.7% |
| Revenue YoY | 116.7% | — |
| Net Profit YoY | 38.9% | — |
| EPS (diluted) | $-0.26 | $0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | $6.5M | $3.8M | ||
| Q3 24 | $3.0M | — |
| Q3 25 | $-19.7M | $744.4K | ||
| Q3 24 | $-32.3M | — |
| Q3 25 | — | 36.4% | ||
| Q3 24 | — | — |
| Q3 25 | -314.1% | — | ||
| Q3 24 | -1145.9% | — |
| Q3 25 | -303.5% | 19.7% | ||
| Q3 24 | -1075.7% | — |
| Q3 25 | $-0.26 | $0.05 | ||
| Q3 24 | $-0.43 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $55.0M | $313.5K |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $58.5M | $11.5M |
| Total Assets | $94.8M | $14.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $55.0M | $313.5K | ||
| Q3 24 | $153.6M | — |
| Q3 25 | $58.5M | $11.5M | ||
| Q3 24 | $156.4M | — |
| Q3 25 | $94.8M | $14.5M | ||
| Q3 24 | $197.2M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-19.1M | $5.2M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | 6.93× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $-19.1M | $5.2M | ||
| Q3 24 | $-27.3M | — |
| Q3 25 | — | — | ||
| Q3 24 | $-27.4M | — |
| Q3 25 | — | — | ||
| Q3 24 | -912.0% | — |
| Q3 25 | 0.0% | — | ||
| Q3 24 | 2.1% | — |
| Q3 25 | — | 6.93× | ||
| Q3 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
